Ponce Aurora is developing consumer products powered by its proprietary MitoXcel™ Technology, the first information- and AI-driven mitochondrial-targeted geropeptides addressing a fundamental cause of aging. Appointment strengthens leadership team to drive market readiness for YUUTH- and…
PrintBio, a regenerative medicine and bioprinting company, today announced its participation in a major ARPA-H PRINT Program initiative aimed at addressing the nation’s growing organ shortage through the development of…
DELIVER Therapeutics, Inc. (“DELIVER”) a company that plans to apply novel, high-throughput screening technologies combined with chemical innovation to DELIVER therapeutics that address the most difficult problems in clinical medicine has been launched with an initial $3M Convertible Note financing by Rapha Capital BioVentures Fund I, LP
Dr. Kevin Slawin, MD, Founder, Chairman and CEO of Deliver Therapeutics, Inc., presented the company at this year’s Alexandria Seed Capital Platform’s Seed Catalyst Partnership Meeting held at The Alexandria…
© 2026 DELiver Therapeutics. Privacy Policy
